Abstract: A new beta coronavirus, labelled as SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), is the pathogen responsible for this worldwide health concern. There have been 2,616,242 confirmed cases and 449,681 fatalities with SARS-CoV-2. The spread of this epidemic has caused healthcare institutions all around the globe to face various difficulties. The therapeutic methods that deal with COVID-19 infection now rely heavily on supportive measures, such as oxygen supplementation, as well as mechanical ventilation and vaccines, and community-wide infection spread reduction, which are the best weapons we have. The illness is difficult to test and has shown resistance to novel treatment medicines, but drugs that are already known to be safe, effective, and with a defined dose may provide a promising option. While they are neither particular nor exact, they are general. Many of these medicines are undergoing clinical studies, and thus far, their effectiveness and safety have been examined for COVID-19 treatment. While some of these methods need to be validated in rigorous preclinical models and clinical trials, recent research has identified other viable treatment alternatives. The following is a short overview that is meant to highlight the recent developments in combating SARS-CoV-2.

Keywords: SARS-CoV-2, ventilation, drug reposition, clinal trials

| DOI: 10.17148/IARJSET.2021.88117